De-risking neurology drug development with better mouse models

Today we welcome Brandy Wilkinson, CEO of GemPharmatech, and Rikki Feng, the company’s Neuroscience Pipeline Leader. Our discussion focuses on a persistent challenge in drug development: neurology’s stubbornly high clinical failure rates. GemPharmatech is tackling this head-on with proprietary models for Alzheimer’s, Parkinson’s, and blood-brain barrier transport that better mirror human disease biology.We explore why mouse models matter more in neurology than in other fields, the design principles behind these next-generation tools, and how smarter preclinical partnerships can help therapeutic developers de-risk programs earlier. 00:00 Welcome Brandy Wilkinson and Rikki Feng03:17 GemPharmatech's mission06:26 Why mouse models matter in neurology11:11 Common translation gaps in neurology18:09 Designing proprietary neurological disease models25:45 Building stronger CRO strategic partnerships33:58 An optimistic future of neuroscience researchThis episode was produced with the support of GemPharmatech. Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Neurological diseases R&D trends and breakthrough innovationsBrain Awareness Week: could ongoing R&D spur neuroscience breakthroughs?11 neuroscience biotech companies you should know about